Deal of the Day — limited-time pharmacy picks!
Hertab 250mg Tablet

Hertab 250mg Tablet

Prescription requiredRx Required

Salt Composition: Lapatinib

Expiry Date: 01/2028

Special offer

Buy at $126.46

$126.46

Inclusive of all taxes

▼

30 Tablets in Bottle

About The Product

Breast Cancer

Description

Hertab 250mg Tablet is a prescription based anticancer medicine with Lapatinib as an active ingredient. It is used in the treatment of advanced or HER2 Positive metastatic breast cancer.

It works against specific proteins to inhibit the growth and spread of cancer cells. This tablet can be either used alone or in combination with some other medicine to cure advanced-stage breast cancer.

Uses

  • Breast cancer

Side Effects

Side effects are unwanted symptoms that can occur from any medical treatment. Like other medications, the Hertab 250mg Tablet can also have adverse effects on the body, most of which resolve without the need for medical attention.
Some common side effects include:

  • Abdominal pain
  • Back pain
  • Breathing problems
  • Constipation
  • Cough
  • Diarrhea
  • Fatigue
  • Headache
  • Hot flashes
  • Increased bilirubin in the blood
  • Insomnia (difficulty sleeping)
  • Joint pain
  • Liver damage
  • Loss of appetite
  • Mucosal inflammation
  • Nausea
  • Pain in extremities
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Vomiting
  • Weakness
  • Weight gain

Seek medical attention in case of any unusual or severe side effects immediately.

How To Use

  • The dosage and duration of the Hertab 250mg Tablet are decided by the doctor based on the severity of the cancer and other health factors.
  • Take this tablet on an empty stomach for better results. Before starting this medicine, please inform your doctor about your medical history.
  • If you experience any signs and symptoms while eating this medication that are not manageable, do not ignore those symptoms because they may lead to a higher risk.


How It Works

Hertab 250mg Tablet is a prescription based anticancer medicine with Lapatinib as an active ingredient. It is a tyrosine kinase inhibitor that works by inhibiting the action of HER2 and EGFRs receptors that promote the uncontrolled growth of cancer cells.

As a result, it stops the growth of cancerous cells and slows down the progression of cancer.

Safety Advice

Alcohol
Avoid the consumption of alcohol while taking Hertab 250mg Tablet, as alcohol can decrease the effectiveness of the medicine as well as worsen the symptoms.
Pregnancy
Do not take Hertab 250mg Tablet without consulting the doctor in case of pregnancy, as it can be unsafe to take it during this period.
Breast Feeding
Breastfeeding women should discuss the potential risks and benefits of the Hertab 250mg Tablet with their healthcare provider before starting treatment.
Driving
Hertab 250mg Tablet may cause side effects such as dizziness or lack of concentration, which could affect your ability to drive. So it's better to avoid driving.
Kidney
Share your medical history with the doctor before starting the Hertab 250mg Tablet. Do not take it without consulting a doctor if you have any kidney related issue.
Liver
Share your medical history with the doctor before starting the Hertab 250mg Tablet. Do not take it without consulting a doctor if you have any liver related issue.

FAQs

Hertab 250mg Tablet is used to treat advanced or HER2 Positive metastatic breast cancer as prescribed by the doctor.

References

  • Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., De Azambuja, E., Aura, C., ... & Piccart-Gebhart, M. (2012). Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. The Lancet, 379(9816), 633-640. https://pubmed.ncbi.nlm.nih.gov/22257673/
  • Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., ... & Steeg, P. S. (2008). Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. Journal of the National Cancer Institute, 100(15), 1092-1103. https://pubmed.ncbi.nlm.nih.gov/18664652/
  • D’Amato, V., Raimondo, L., Formisano, L., Giuliano, M., De Placido, S., Rosa, R., & Bianco, R. (2015). Mechanisms of lapatinib resistance in HER2-driven breast cancer. Cancer treatment reviews, 41(10), 877-883. https://pubmed.ncbi.nlm.nih.gov/26276735/
  • Opdam, F. L., Guchelaar, H. J., Beijnen, J. H., & Schellens, J. H. (2012). Lapatinib for advanced or metastatic breast cancer. The oncologist, 17(4), 536-542. https://pubmed.ncbi.nlm.nih.gov/22477724/
  • Moy, B., & Goss, P. E. (2006). Lapatinib: current status and future directions in breast cancer. The oncologist, 11(10), 1047-1057. https://pubmed.ncbi.nlm.nih.gov/17110623/
  • Bilancia, D., Rosati, G., Dinota, A., Germano, D., Romano, R., & Manzione, L. (2007). Lapatinib in breast cancer. Annals of oncology, 18, vi26-vi30. https://pubmed.ncbi.nlm.nih.gov/17591827/

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026